Deep-dive AI research reports on individual stocks, powered by our proprietary signals. Every report carries a direction (Bullish or Bearish) and a conviction level(Strong or Speculative). We track stock performance since each report's publication date — because we believe great analysis should be held accountable.

The GLP-1 Myopia: Why Wall Street Just Handed Us Wave Life Sciences at a 65% Discount

2026-04-01BullishStrongChange from report: -49.3%1M: +7.2%3M: -14.5%

Wave Life Sciences' stock crashed 50% on obesity drug data. But the drug targets toxic fat & preserves muscle, unlike GLP-1s. Insiders are buying, seeing a misunderstood RNA editing pioneer, not a failure.